NEWS
SUBSCRIBER SEARCH (Requires Login)
  NEW DRUGS
  MARKETED DRUGS
  COMPANY
  TARGETS IN ONCOLOGY
  NEWS SUMMARIES
  COMBINATION TRIALS

Latest Updates

February 2010 Marketed Drug Updates and Additions

Brand Name

Generic Name

Other Designation

Vectibix

Panitumumab

ABX-EGF (formerly known as clone E7.6.3)

Trellasar, De-Capeptyl (UK), Trelstar LA (USA), Trelstar Depot (USA), Decapeptyl (Europe), Pamorelin (Germany)

Triptorelin pamoate

D-TRP-6-LHRH, Debio 8206

D-TRP-6-LHRH, Debio 8206

Catumaxomab

 

Hycamtin, Hycaptamine

Topotecan

NSC-609699, SK&F-104864

Tykerb (USA, EU), Tyverb

Lapatinib ditosylate

572016, GW572016, GW 572016, GSK 572016

Arzerra

Ofatumumab

HuMax-CD20, GSK1841157

Gardasil, Silgard (Eastern Europe)

Quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine

 

Proleukin

Aldesleukin (IL-2)

NSC-373364

 

 

WF10

Tarceva

Erlotinib

CP 358774, OSI-774, R1415, RG1415, NSC 718781

Celebrex (formerly known as Celebra)

Celecoxib

SC-236, SC-58635

Nikidess, Aromasin

Exemestane

FCE 24304

Sutent

Sunitinib malate

SU011248, SU11248, SU-11248

Glutoxim (Russia)

 

BAM-002, NOV-002 (USA)

  

Home   |    Freelance Opportunities   |   New Medicine   |   Site Map   |  Order/Inquiry   
SUBSCRIBER SEARCH:   NEW DRUG   |   MARKETED DRUG   |   COMPANY   |   TARGETS IN ONCOLOGY  

NEW MEDICINE, INC.
P.O. BOX 909, LAKE FOREST, CA 92609
PHONE:  1-949-830-0448     FAX:  1-949-830-0887
INFO@NEWMEDINC.COM